Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 80%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Summary of findings: Octreotide vs placebo · Diarrhoea (grade 2+)
  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.76, 1.35]
  2 studies · 340 participants
  Moderate
Direct match · question page
- Summary of findings: Octreotide vs placebo · Acute and late GI toxicity (grade 2+)
  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Summary of findings: Octreotide vs placebo · Mean GI symptom scores
  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Summary of findings: Octreotide vs placebo · Outcomes1
  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Summary of findings: Octreotide vs placebo · QOL scores
  Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

Outcomes1 · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Octreotide vs placebo

Mean GI symptom scores · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Octreotide vs placebo

Acute and late GI toxicity (grade 2+) · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Octreotide vs placebo

Diarrhoea (grade 2+) · People undergoing RT for pelvic cancer

Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.01 [0.76, 1.35]
2 studies · 340 participants
Moderate

Summary of findings: Octreotide vs placebo

QoL · People undergoing RT for pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found